Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJNeurology is excited to bring you updates from the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024), which took place in Copenhagen, Denmark. This meeting brought together experts to discuss the latest advancements in the management and understanding of multiple sclerosis.

ECTRIMS 2024

The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
18–20 September 2024 | Copenhagen, Denmark

ECTRIMS 2024

The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
18–20 September 2024 | Copenhagen, Denmark
VJNeurology is excited to bring you updates from the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024), which took place in Copenhagen, Denmark. This meeting brought together experts to discuss the latest advancements in the management and understanding of multiple sclerosis.
Investigating CAR T-cell therapy in the treatment of MS 2:14
Investigating CAR T-cell therapy in the treatment of MS
Krish Patel • 21 Sep 2024
Investigating evobrutinib and other BTK inhibitors for the treatment of MS 3:05
Investigating evobrutinib and other BTK inhibitors for the treatment of MS
Anneke van der Walt • 7 Oct 2024
The evolving understanding of the disease course in MS 1:49
The evolving understanding of the disease course in MS
Emilio Portaccio • 17 Oct 2024
The importance of a multi-disciplinary team in MS lifestyle management 1:42
The importance of a multi-disciplinary team in MS lifestyle management
Anneke van der Walt • 7 Oct 2024
Disability accrual in MS: RAW versus PIRA 1:58
Disability accrual in MS: RAW versus PIRA
Emilio Portaccio • 17 Oct 2024
Improving the global applicability of the new MS diagnostic criteria 1:49
Improving the global applicability of the new MS diagnostic criteria
Marcello Moccia • 24 Oct 2024
The implementation of the new MS diagnostic criteria into clinical practice 2:57
The implementation of the new MS diagnostic criteria into clinical practice
Marcello Moccia • 24 Oct 2024
How a better understanding of RAW and PIRA may improve outcomes & therapeutic interventions in MS 1:54
How a better understanding of RAW and PIRA may improve outcomes & therapeutic interventions in MS
Emilio Portaccio • 17 Oct 2024
The impact of dietary patterns on MS: what remains unknown 2:07
The impact of dietary patterns on MS: what remains unknown
Anneke van der Walt • 7 Oct 2024
Barriers to the treatment of MS in the MENA region 2:55
Barriers to the treatment of MS in the MENA region
Maya Zeineddine • 4 Oct 2024
Adverse events associated with natalizumab in MS and advice on mitigating them 1:17
Adverse events associated with natalizumab in MS and advice on mitigating them
Maya Zeineddine • 4 Oct 2024
Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS 1:50
Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS
Maya Zeineddine • 4 Oct 2024
Lower cognitive performance before MS symptom onset: a Norweigan study 1:57
Lower cognitive performance before MS symptom onset: a Norweigan study
Helen Tremlett • 9 Oct 2024
The clinical significance of a prodromal phase in MS 3:35
The clinical significance of a prodromal phase in MS
Helen Tremlett • 9 Oct 2024
The concept of an MS prodomal phase and how it has long been neglected 1:29
The concept of an MS prodomal phase and how it has long been neglected
Helen Tremlett • 9 Oct 2024
Increased healthcare use before MS onset as evidence for a potential prodromal phase 3:04
Increased healthcare use before MS onset as evidence for a potential prodromal phase
Helen Tremlett • 9 Oct 2024
The content of VJNeurology is intended for healthcare professionals